Core Insights - Traws Pharma's ongoing clinical results with ratutrelvir indicate a differentiated profile compared to PAXLOVID, showing fewer adverse events, no viral rebounds to date, and faster time to sustained symptom resolution, particularly in PAXLOVID-ineligible patients [1][4][9] - The company is also advancing tivoxavir marboxil, which is predicted to provide 28-day protection against a wide range of seasonal and pandemic influenza variants [1][5][6] Ratutrelvir Update - The Phase 2 study of ratutrelvir is an active-controlled trial against PAXLOVID, focusing on patient-reported outcomes, safety, and usability [2] - Patients in the ratutrelvir arm received 600 mg orally once daily for 10 days, while the comparator arm received PAXLOVID as per approved guidelines [3] - The data suggests ratutrelvir may benefit a broader range of patients, especially those unable to receive ritonavir-boosted therapy, with a favorable tolerability profile and absence of viral rebound events [4] Tivoxavir Marboxil Update - Traws Pharma is progressing tivoxavir marboxil as a single monthly oral tablet for prophylactic treatment of seasonal influenza [5] - Previous Phase 1 studies indicated that a powder-in-capsule formulation provided blood levels exceeding 3X the EC50 for common seasonal influenza variants for up to 22 days [6] - A new compressed tablet formulation is expected to provide 28-day coverage, with a challenge study planned for June 2026 [7] Market Opportunity - The COVID treatment market represents a potential multi-billion dollar opportunity, with ratutrelvir targeting the Main protease (Mpro) of SARS-CoV-2 [9] - Seasonal influenza also represents a significant multi-billion dollar market opportunity, driven by global health organizations and potential pandemic flu outbreaks [10]

Core Insights - Traws Pharma has filed a U.S. IND application for tivoxavir marboxil (TXM), a potential treatment for influenza, marking a significant step towards its inclusion in the strategic national stockpile [1][3][4] - Updated clinical results for ratutrelvir indicate a favorable profile compared to PAXLOVID, with fewer adverse events, no viral rebounds, and quicker symptom resolution, particularly in patients ineligible for PAXLOVID [1][5][8] Company Developments - Traws Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for respiratory viral diseases, including COVID-19 and influenza [18] - The company is advancing ratutrelvir as a ritonavir-independent treatment for COVID-19, targeting the Main protease (Mpro or 3CL protease) [18] - Traws Pharma is also developing tivoxavir marboxil as a single-dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease [18] Clinical Study Insights - The ongoing Phase 2 study of ratutrelvir has enrolled 50 patients, with 95% of the planned 90-patient population already enrolled [6] - Interim analysis shows that ratutrelvir-treated patients had a time to sustained symptom resolution of 12 days compared to 14 days for PAXLOVID-treated patients (p<0.014) [8][9] - Ratutrelvir demonstrated a better safety profile, with only 7.6% of patients reporting mild dyspepsia, while 30% of PAXLOVID patients reported adverse events [11][12] Market Potential - The seasonal influenza market represents a multi-billion dollar opportunity, driven by global health organizations and government initiatives [15] - The COVID-19 treatment market also presents significant potential, with ratutrelvir positioned as a next-generation oral 3CL protease inhibitor [14][15]

Invivyd Q3 Earnings Call & Business Update November 6, 2025 © 2025 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners. 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," ...